JP2005512016A - Ａ２スーパーモチーフを有するサブユニットワクチン - Google Patents

Ａ２スーパーモチーフを有するサブユニットワクチン Download PDF

Info

Publication number
JP2005512016A
JP2005512016A JP2002561950A JP2002561950A JP2005512016A JP 2005512016 A JP2005512016 A JP 2005512016A JP 2002561950 A JP2002561950 A JP 2002561950A JP 2002561950 A JP2002561950 A JP 2002561950A JP 2005512016 A JP2005512016 A JP 2005512016A
Authority
JP
Japan
Prior art keywords
peptide
antigen
amino acid
peptides
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002561950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512016A5 (enExample
Inventor
ジョン シドニー，
アレサンドロ セッテ，
ハワード エム． グレイ，
スコット サウスウッド，
Original Assignee
エピミューン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピミューン インコーポレイテッド filed Critical エピミューン インコーポレイテッド
Publication of JP2005512016A publication Critical patent/JP2005512016A/ja
Publication of JP2005512016A5 publication Critical patent/JP2005512016A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2002561950A 2001-01-29 2002-01-29 Ａ２スーパーモチーフを有するサブユニットワクチン Pending JP2005512016A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26496901P 2001-01-29 2001-01-29
US09/935,476 US20040096445A1 (en) 1999-06-30 2001-08-22 Subunit vaccines with A2 supermotifs
PCT/US2002/002708 WO2002061435A2 (en) 2001-01-29 2002-01-29 Subunit vaccines with a2 supermotifs

Publications (2)

Publication Number Publication Date
JP2005512016A true JP2005512016A (ja) 2005-04-28
JP2005512016A5 JP2005512016A5 (enExample) 2006-01-05

Family

ID=26950859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002561950A Pending JP2005512016A (ja) 2001-01-29 2002-01-29 Ａ２スーパーモチーフを有するサブユニットワクチン

Country Status (14)

Country Link
US (1) US20040096445A1 (enExample)
EP (1) EP1368659A2 (enExample)
JP (1) JP2005512016A (enExample)
KR (1) KR20040052475A (enExample)
CN (1) CN1653337A (enExample)
AU (1) AU2002243730B2 (enExample)
CA (1) CA2432995C (enExample)
CZ (1) CZ20032054A3 (enExample)
IL (1) IL156660A0 (enExample)
MX (1) MXPA03006581A (enExample)
NZ (1) NZ526860A (enExample)
RU (1) RU2003126447A (enExample)
SK (1) SK9512003A3 (enExample)
WO (1) WO2002061435A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
EP1078092B1 (en) * 1998-05-13 2011-08-03 Epimmune Inc. Expression vectors for stimulating an immune response and methods of using the same
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
CN110214275B (zh) * 2016-12-01 2022-12-06 南托米克斯有限责任公司 肿瘤抗原性加工和呈递

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370413A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU2605501A (en) * 1999-12-21 2001-07-03 Epimmune, Inc. Inducing cellular immune responses to prostate cancer antigens using peptide andnucleic acid compositions

Also Published As

Publication number Publication date
EP1368659A2 (en) 2003-12-10
CA2432995A1 (en) 2002-08-08
NZ526860A (en) 2007-03-30
KR20040052475A (ko) 2004-06-23
SK9512003A3 (en) 2003-12-02
IL156660A0 (en) 2004-01-04
AU2002243730B2 (en) 2007-07-12
WO2002061435A3 (en) 2003-07-10
WO2002061435A2 (en) 2002-08-08
US20040096445A1 (en) 2004-05-20
RU2003126447A (ru) 2005-02-27
CA2432995C (en) 2011-07-26
CN1653337A (zh) 2005-08-10
CZ20032054A3 (cs) 2003-12-17
MXPA03006581A (es) 2004-06-25

Similar Documents

Publication Publication Date Title
EP1917970B1 (en) Hla binding peptides and their uses
JP4873810B2 (ja) ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
JP4210734B2 (ja) Ｈｌａ結合ペプチド及びその使用
JP3908271B2 (ja) Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
JP6006265B2 (ja) Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
JP4210735B2 (ja) Ｈｌａ―ａ２．１結合ペプチド及びその使用
EP1911461A2 (en) HLA class I and II binding peptides and their uses
JP2003509465A (ja) ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
JP2002507397A (ja) Ｈｌａ結合ペプチド及びその使用
JP2003521243A (ja) ヘテロクリティックアナログおよび関連方法
JP2004508320A (ja) ペプチドおよび核酸組成物を用いるｂ型肝炎ウイルスに対する細胞性免疫応答の誘導
JP2003524016A (ja) Ｈｌａ結合ペプチドおよびそれらの用途
JP2010090167A (ja) Ｈｌａ結合ペプチドおよびそれらの用途
JP2005512016A (ja) Ａ２スーパーモチーフを有するサブユニットワクチン
US20040157273A1 (en) Subunit vaccines with a2 supermotifs
AU2002243730A1 (en) Subunit vaccines with A2 supermotifs
JP2004517609A (ja) Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
JP2004522415A (ja) Ｈｌａ結合ペプチドおよびその使用方法
EP1767542B1 (en) HLA-A2.1 binding peptides and their uses
CA2421448A1 (en) Hla binding peptides and their uses
JP2010001303A (ja) Ｈｌａ結合ペプチド及びその使用
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080520

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081008